title: [Long term survival results in advanced prostate cancer treated with combined androgen blockade].
abstract: OBJECTIVE
  To understand long-term survival rate after combined androgen blockade (CAB) in patients with advanced prostate cancer.
  
  
  METHODS
  A selected population of 59 patients with advanced prostate cancer were treated with CAB. 28.81% (17/59) of patients had clinical locally advanced disease (stage T3-4N0M0), and 45.76% (27/59) of patients had metastatic disease (stage TxNxM+). Overall, patients were followed for a median of 62 (range 6-136) months.
  
  
  RESULTS
  Of the 59 patients with advanced prostate cancer, 3-year, 5-year and 7-year overall survival rates were 79.36%, 61.46% and 49.15%, respectively. The 5-year survival rate were 80.77% and 32.65% for clinical locally advanced disease and metastatic disease. Specifically, men with poorly differentiated prostate cancer had a 5-year survival of only 30% when compared with men with well-differentiated prostate disease who had a 5-year survival of 86.21%.
  
  
  CONCLUSIONS
  Based on these findings, men with poorly differentiated cancer, stage T3c-4NxMx or TxNxM+ and PSA level above 30 microg/L had a high probability of dying from their advanced prostate cancer.
authors.affiliation: Department of Urology, Jiangsu Geriatric Hospital, Nanjing, Jiangsu 210024, China.
authors.forename: Shi-ge
authors.initials: SG
authors.lastname: Zhang
authors.forename: Yi-hua
authors.initials: YH
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Ding
authors.forename: Ye
authors.initials: Y
authors.lastname: Wu
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005485:Flutamide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D005485:Flutamide